Figure 2.

Cold versus hot tumors. Treatment schedule recommended according to the type of tumor. Hot tumors are characterized by high lymphocyte infiltration and PD-L1 expression, resulting in good clinical responses with anti PD-1/PD-L1 monoclonal antibodies, unlike cold tumors. Our hypothesis regarding cold tumors is to treat them with DC vaccines, which have been shown to increase lymphocyte infiltration and PD-L1 expression, and then, in a second step, to incorporate the anti-PD-1/PD-L1 monoclonal antibodies into the treatment in order to improve clinical responses.